Phase 2 des nouveaux ARVs
Fostemsavir, prodrug of temsavir (attachment inhibitor)
TAF (TFV prodrug)
Doravirine (non nucleoside reverse transcriptase inhibitor)
Cabotegravir (integrase inhibitor)
Bictegravir
Islatravir (ISL)